Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Major Shareholder Perceptive Advisors Llc Buys 309,847 Shares of Stock

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) major shareholder Perceptive Advisors Llc bought 309,847 shares of the stock in a transaction dated Wednesday, April 3rd. The stock was bought at an average price of $4.09 per share, with a total value of $1,267,274.23. Following the acquisition, the insider now owns 9,097,858 shares in the company, valued at approximately $37,210,239.22. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Perceptive Advisors Llc also recently made the following trade(s):

• On Monday, April 1st, Perceptive Advisors Llc acquired 8,374 shares of Aldeyra Therapeutics stock. The stock was bought at an average price of $3.25 per share, with a total value of $27,215.50.

Aldeyra Therapeutics Stock Up 16.9 %

Shares of ALDX stock opened at $4.15 on Thursday. Aldeyra Therapeutics, Inc has a 52-week low of $1.42 and a 52-week high of $11.97. The stock’s 50-day moving average price is $3.34 and its 200 day moving average price is $3.42. The stock has a market capitalization of $244.44 million, a PE ratio of -6.48 and a beta of 1.51.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.13. Analysts expect that Aldeyra Therapeutics, Inc will post -0.26 earnings per share for the current fiscal year.

Institutional Trading of Aldeyra Therapeutics

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Aldeyra Therapeutics by 23.2% in the fourth quarter. Vanguard Group Inc. now owns 3,927,597 shares of the biotechnology company’s stock valued at $13,786,000 after buying an additional 740,177 shares in the last quarter. BlackRock Inc. lifted its holdings in Aldeyra Therapeutics by 228.0% in the second quarter. BlackRock Inc. now owns 3,230,414 shares of the biotechnology company’s stock valued at $27,103,000 after acquiring an additional 2,245,432 shares during the period. State Street Corp boosted its position in shares of Aldeyra Therapeutics by 1,655.5% during the 2nd quarter. State Street Corp now owns 3,041,866 shares of the biotechnology company’s stock worth $25,521,000 after purchasing an additional 2,868,585 shares in the last quarter. Knoll Capital Management LLC grew its stake in shares of Aldeyra Therapeutics by 45.9% during the 2nd quarter. Knoll Capital Management LLC now owns 3,015,668 shares of the biotechnology company’s stock worth $25,301,000 after purchasing an additional 948,508 shares during the period. Finally, Verition Fund Management LLC increased its holdings in shares of Aldeyra Therapeutics by 54.1% in the 1st quarter. Verition Fund Management LLC now owns 2,105,907 shares of the biotechnology company’s stock valued at $9,361,000 after purchasing an additional 739,206 shares in the last quarter. Institutional investors and hedge funds own 59.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. StockNews.com raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, January 29th. Oppenheimer upgraded Aldeyra Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Tuesday.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.